Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Jian-Ping WengLongyi ZengYuwei ZhangShen QuXueying WangPing LiLiujun FuBoqing MaShandong YeJiao SunWeiping LuZhiwen LiuDaoxiong ChenZhifeng ChengHaiyan LiuTao ZhangJianjun ZouPublished in: Diabetes, obesity & metabolism (2021)
Henagliflozin 5 mg or 10 mg as add-on therapy to metformin provided a new therapeutic option for the treatment of T2DM patients who have inadequate glycaemic control with metformin alone, and was generally well tolerated.
Keyphrases
- double blind
- placebo controlled
- clinical trial
- phase iii
- phase ii
- study protocol
- end stage renal disease
- ejection fraction
- newly diagnosed
- type diabetes
- phase ii study
- chronic kidney disease
- open label
- prognostic factors
- squamous cell carcinoma
- mesenchymal stem cells
- bone marrow
- cell therapy
- skeletal muscle
- stem cells
- metabolic syndrome
- rectal cancer
- combination therapy